Preclinical safety studies with Temofel, a new choleretic compound

Area of Science:

• Pharmacology
• Toxicology
• Preclinical Research

Background:

• Temofel (2,5-dimethyl-alpha-ethyl-benzhydrol) is a choleretic compound.
• Preclinical safety assessments are crucial for advancing compounds into clinical trials.

Purpose of the Study:

• To evaluate the safety profile of Temofel for potential Phase I and II clinical trials.
• To identify potential toxicological endpoints and establish safe dosage ranges.

Main Methods:

• Acute toxicity studies in mice and dogs to assess CNS, haemodynamic, and respiratory effects.
• Sub-chronic (28-day) oral toxicity studies in rats and dogs at various dose levels.
• Chronic (6-month) oral toxicity studies in rats and dogs at varying concentrations/doses.

Main Results:

• Temofel did not exhibit oestrogenic, anti-oestrogenic, androgenic, or anti-androgenic effects in rats.
• Rats administered high doses (≥320 mg/kg) in a 28-day study showed hepatic and renal toxicity, and testicular atrophy.
• Dogs showed sporadic increases in SAP activity at high doses.
• Long-term studies in rats indicated growth retardation and reproductive toxicity (testicular atrophy, impaired spermatogenesis) at higher doses, but notably less hepatic/renal damage compared to short-term gavage studies.

Conclusions:

• Temofel exhibits a dose-dependent toxicity profile, with significant adverse effects on the liver, kidneys, and reproductive system at higher doses.
• While initial acute studies showed no major safety concerns, sub-chronic and chronic studies highlight the need for careful dose selection and monitoring in future clinical development.
• Further investigation into the mechanisms of observed toxicity and potential reversibility is warranted.